Abstract
Introduction Hand conditions in diabetes, namely limited joint mobility (LJM), flexor tenosynovitis (FT), carpal tunnel syndrome (CTS), and Dupuytren disease (DD), share a common pathophysiological process involving pro-fibrotic inflammation in flexor structures. A unified, quantitative measure of disease severity across these conditions is lacking, limiting correlational research. We evaluated mean metacarpophalangeal (MCP) joint extension as a potential measure of severity.
Methods We assessed 2405 adults, including individuals with type 1 diabetes (n=291), type 2 diabetes (n=877), prediabetes (n=326), and non-diabetic controls (n=911). MCP extension was calculated as the average maximum passive extension of the 2nd-5th fingers, measured with a protractor. Validity was determined by correlating MCP extension with physician-rated severity (convergent) and hand grip strength and the Duruoz Hand Index (DHI, both divergent). Inter-rater reliability was tested in 128 individuals, and sensitivity to change was evaluated in 143 participants over time and in 21 rheumatology patients with subacute noninfectious FT.
Results Mean MCP extension was significantly lower in individuals with all hand conditions (42.4° LJM, 42.8° FT, 39.9° DD, 51.7° CTS) than in those without (58.6°, all p<0.05). MCP extension correlated with physician-rated severity (−0.5, p<0.01) and weakly with DHI (R2=0.03) and grip strength (R2=0.07). Inter-rater reliability was strong (ICC 0.72), and MCP extension demonstrated sensitivity to change, worsening over eight months (SRM -0.61) and improving after treatment in subacute FT (SRM 0.69).
Conclusion Mean MCP extension is a valid, reliable, and responsive measure for assessing fibro-inflammatory hand conditions in diabetes, suitable for use in research studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded through a DBT/Wellcome India Alliance Clinical and Public health fellowship (IA/CPHE/19/504607, awarded to SP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of KEM Hospital Research Centre gave ethical approval for this work (KEMHRC/RVC/EC/1518)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
